Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice

Area of Science:

• Nephrology
• Diabetology
• Pharmacology

Background:

• Diabetic nephropathy (DN) is a primary cause of end-stage renal disease (ESRD), with current renin-angiotensin-aldosterone system (RAAS) inhibitors offering only partial protection.
• Nitro-oleic acid (OA-NO2) has shown renoprotective effects in previous rodent studies.

Purpose of the Study:

• To investigate the therapeutic efficacy and mechanism of combining losartan with OA-NO2 in a mouse model of diabetic nephropathy.
• To evaluate the combined treatment's impact on kidney injury markers, oxidative stress, and inflammation.

Main Methods:

• Diabetic db/db mice were treated for 2 weeks with either losartan, OA-NO2, or a combination of both.
• Kidney injury, albuminuria, glomerulosclerosis, podocyte loss, fibrosis, oxidative stress, and inflammation were assessed.

Main Results:

• Both losartan and OA-NO2 alone moderately reduced kidney injury.
• Combined treatment significantly decreased albuminuria, improved glomerular filtration barrier structure, and attenuated glomerulosclerosis.
• The combination therapy markedly suppressed renal oxidative stress and inflammation.

Conclusions:

• Combination therapy with losartan and OA-NO2 effectively reverses renal injury in diabetic nephropathy.
• This synergistic approach presents a potential new strategy for managing DN and preventing ESRD progression.